WO2001022919A3 - Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof - Google Patents
Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof Download PDFInfo
- Publication number
- WO2001022919A3 WO2001022919A3 PCT/US2000/026387 US0026387W WO0122919A3 WO 2001022919 A3 WO2001022919 A3 WO 2001022919A3 US 0026387 W US0026387 W US 0026387W WO 0122919 A3 WO0122919 A3 WO 0122919A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- benign prostatic
- prostatic hyperplasia
- alpha
- azacycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU77166/00A AU7716600A (en) | 1999-09-30 | 2000-09-26 | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15720799P | 1999-09-30 | 1999-09-30 | |
| US60/157,207 | 1999-09-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001022919A2 WO2001022919A2 (en) | 2001-04-05 |
| WO2001022919A3 true WO2001022919A3 (en) | 2002-07-11 |
Family
ID=22562765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/026387 WO2001022919A2 (en) | 1999-09-30 | 2000-09-26 | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU7716600A (en) |
| WO (1) | WO2001022919A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085354A1 (en) | 2001-04-18 | 2002-10-31 | Euro-Celtique S.A. | Spiroindene and spiroindane compounds |
| AU2004222336B2 (en) * | 2003-03-18 | 2010-06-03 | Merck Sharp & Dohme Corp. | Amino cyclobutylamide modulators of chemokine receptor activity |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| MX2007002033A (en) | 2004-08-19 | 2007-04-26 | Vertex Pharma | Modulators of muscarinic receptors. |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| RU2007124373A (en) | 2004-11-29 | 2009-01-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | MUSCARINE RECEPTION MODULATORS |
| JP2009521483A (en) | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Muscarinic receptor modulators |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| RU2008137593A (en) | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | MUSCARINE RECEPTOR MODULATORS |
| AU2007221220A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| EP2040706A2 (en) | 2006-06-29 | 2009-04-01 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
| EP2051712A2 (en) | 2006-08-15 | 2009-04-29 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
| JP2010501561A (en) | 2006-08-18 | 2010-01-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Modulator of muscarinic receptor |
| EP2207549A1 (en) | 2007-10-03 | 2010-07-21 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995028397A1 (en) * | 1994-04-14 | 1995-10-26 | Merck & Co., Inc. | Alpha1c adrenergic receptor antagonists |
-
2000
- 2000-09-26 WO PCT/US2000/026387 patent/WO2001022919A2/en active Application Filing
- 2000-09-26 AU AU77166/00A patent/AU7716600A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995028397A1 (en) * | 1994-04-14 | 1995-10-26 | Merck & Co., Inc. | Alpha1c adrenergic receptor antagonists |
Non-Patent Citations (1)
| Title |
|---|
| DHAR T.G. ET AL.: "Design and synthesis of novel alpha 1a andrenoceptor-selective antagonists. 2. Approaches to eliminate opiod agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety", J. MED. CHEM., vol. 42, no. 23, October 1999 (1999-10-01), pages 4778 - 4793, XP002949069 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001022919A2 (en) | 2001-04-05 |
| AU7716600A (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001022919A3 (en) | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof | |
| MX9703518A (en) | Dihydropyrimidines and uses thereof. | |
| AU2088597A (en) | Antagonism of endothelin actions | |
| WO1998051311A3 (en) | Dihydropyrimidines and uses thereof | |
| AU5090796A (en) | Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence | |
| WO1999046279A3 (en) | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| TR199901417T2 (en) | New compositions with analgesic effect. | |
| BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
| NZ512883A (en) | 2-oxoquinoline compounds and medicinal uses thereof | |
| UY26082A1 (en) | DERIVATIVES OF 1,4-DIAZABICICLO [3.2.2] NONAN-4-CARBOXILATO AND -CARBOXAMIDAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| WO2002036562A3 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
| EE200100458A (en) | A pharmaceutical agent in combination with a proton pump inhibitor or H2 receptor antagonist and a pharmaceutical composition containing them for use in the treatment of gastrointestinal disorders. | |
| RU2001130354A (en) | LOCAL USE OF ANTIANDROGEN FROM LOSS OF HAIR AND OTHER HYPERANDROGENIC STATES | |
| BR9915134A (en) | Co-therapy and combination therapy for the treatment of cardiovascular disorders in an individual, and composition | |
| MY133423A (en) | Pharmaceutical combinations and their use in treating gastrointestinal disorders | |
| ATE320796T1 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF ANAL INCONTINENCE AND ANAL ITCHING | |
| RU2002105377A (en) | XENON ANTAGONIST NMDA | |
| BR0109515A (en) | Apomorphine Derivatives and Methods for Their Use | |
| DK1148881T3 (en) | Use of pyridazine [4,5-b] indole-1-acetamide derivatives for the preparation of drugs for diseases associated with peripheral benzodiazepine receptors dysfunction | |
| BR0208694A (en) | Use of selective cox-2 inhibitors to treat urinary incontinence | |
| BR0011865A (en) | aromatic and heterocyclic derivatives of phytoterols and / or phytostanols for use in the treatment and prevention of cardiovascular disease | |
| WO2002011747A3 (en) | Transglutaminase for inhibiting angiogenesis | |
| HUP0200969A3 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders os mixed anxiety-depression disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |